Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to...

JAGX : 1.0400 (+5.62%)
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to...

JAGX : 1.0400 (+5.62%)
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases

JAGX : 1.0400 (+5.62%)
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases

JAGX : 1.0400 (+5.62%)
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.

SRNE : 0.0025 (-16.67%)
TNXP : 0.1900 (-6.95%)
IBB : 137.96 (+1.37%)
JAGX : 1.0400 (+5.62%)
NVAX : 8.47 (+5.35%)
INO : 4.07 (+0.25%)
GILD : 90.19 (+0.48%)
MRNA : 41.11 (+7.48%)
VXRT : 0.6000 (+0.12%)
IBIO : 2.64 (+7.76%)
XBI : 96.24 (+2.06%)
PFE : 25.65 (+2.07%)
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Each October, breast cancer awareness gains momentum through impactful campaigns and advancements in...

ONCY : 0.9541 (-2.64%)
PCSA : 0.8601 (-2.26%)
JAGX : 1.0400 (+5.62%)
BCTX : 0.7297 (-7.52%)
ONC.TO : 1.33 (-2.92%)
RHHBY : 35.4400 (+0.43%)
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

FDA-approved Gelclair® is company's third commercialized prescription product

JAGX : 1.0400 (+5.62%)
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

FDA-approved Gelclair® is company's third commercialized prescription product

JAGX : 1.0400 (+5.62%)
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued for core rare disease target indication for crofelemer

JAGX : 1.0400 (+5.62%)
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued for core rare disease target indication for crofelemer

JAGX : 1.0400 (+5.62%)

Barchart Exclusives

How to Invest for Kids: Understanding the Basics
A good way to show kids the value of compounding money is to ask if they’d rather have a $100 bill today or a penny that doubles every day for 30 days. They will be surprised to hear that in 30 days, that penny would be worth about $5.4 million dollars! Here's a guide to the types of accounts you can open for your children or grandchildren. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar